{"filing":{"accession_number":"0001104659-26-089524","cik":"0001356576","ticker":"SUPN","company_name":"SUPERNUS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"tm2622009d4_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465926089524/tm2622009d4_8k.htm"},"events":[{"id":23299,"run_id":21069,"accession_number":"0001104659-26-089524","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The Item 8.01 disclosure announces a proposed merger of equals between Supernus Pharmaceuticals and Indivior Pharmaceuticals, structured as a 100% tax-free stock-for-stock transaction with a fixed exchange ratio of 1.5401 Indivior shares per Supernus share. The filing explicitly states the companies are \"hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger\" and references a joint proxy statement/prospectus to be filed. This is a material acquisition/merger activity that would substantially affect the registrant's business, ownership structure, and financial profile, creating a combined $2.2 billion CNS biopharmaceutical company.","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23495,"accession_number":"0001104659-26-089524","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The Item 8.01 disclosure announces a proposed merger of equals between Supernus Pharmaceuticals and Indivior Pharmaceuticals, structured as a 100% tax-free stock-for-stock transaction with a fixed exchange ratio of 1.5401 Indivior shares per Supernus share. The filing explicitly states the companies are \"hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger\" and references a joint proxy statement/prospectus to be filed. This is a material acquisition/merger activity that would substantially affect the registrant's business, ownership structure, and financial profile, creating a combined $2.2 billion CNS biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:18:11.775572+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23495,"accession_number":"0001104659-26-089524","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The Item 8.01 disclosure announces a proposed merger of equals between Supernus Pharmaceuticals and Indivior Pharmaceuticals, structured as a 100% tax-free stock-for-stock transaction with a fixed exchange ratio of 1.5401 Indivior shares per Supernus share. The filing explicitly states the companies are \"hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger\" and references a joint proxy statement/prospectus to be filed. This is a material acquisition/merger activity that would substantially affect the registrant's business, ownership structure, and financial profile, creating a combined $2.2 billion CNS biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:18:11.775572+00:00","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-08-03"}]}